Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Purple Biotech ( (PPBT) ) has shared an update.
On December 15, 2025, Purple Biotech Ltd. held an Extraordinary General Meeting of Shareholders at its headquarters in Rehovot, Israel. During the meeting, all proposals outlined in the company’s Proxy Statement were approved by the shareholders, in accordance with Israeli Companies Law and the company’s articles of association. This approval signifies a strategic alignment among stakeholders, potentially impacting the company’s future operations and market positioning.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is based in Rehovot, Israel, and is involved in creating solutions that target the tumor microenvironment to enhance the efficacy of existing cancer treatments.
Average Trading Volume: 7,314,316
Technical Sentiment Signal: Sell
Current Market Cap: $8.1M
Find detailed analytics on PPBT stock on TipRanks’ Stock Analysis page.